

Serial No.: 09/683,258
Attorney Docket: 3418

REMARKS

Applicants have amended Claims 18, 20, 28 and 31. Support for the amendment to Claim 18 may be found, for example on page 1 paragraph 3 (lines 20-23), page 2 paragraph 4 (lines 2-6), page 9 paragraph 34 (lines 28-30) and page 16 paragraph 56 (lines 2-6). Support for the amendment to Claim 28 may be found, for example, on page 21 paragraph 71 (lines 21-31) of the Specification. Applicants have also amended pages 16 and 19 of the Specification to correct typographical errors. Applicants respectfully request entry of the above amendments and submit that no new matter is entered by these amendments.

Claims 18-32 are currently pending in this application. A complete listing of currently pending Claims is provided on page 2 of this paper.

Objections to the Specification are Obviated

The Examiner has objected to the Disclosure because it contains embedded hyperlinks. Applicants have amended pages 16 and 19 of the Specification to delete the hyperlinks, thereby obviating this objection.

Objections to the Claims are Obviated

The Examiner has objected to the format of Claim 18. Applicants have amended Claim 18 in order to overcome this objection.

Serial No.: 09/683,258
Attorney Docket: 3418

Claim Rejections under 35 U.S.C. §112, Second Paragraph should be Withdrawn

The Examiner has rejected Claims 18-32 under 35 U.S.C. §112, second paragraph, for allegedly being indefinite.

Claim 18 is rejected because it recites "*the* genomic DNA" which lacks proper antecedent basis and Claims 19-32 are rejected because of their dependence from Claim 18. Applicants respectfully disagree with the Examiner since "inherent components of elements recited have antecedent basis in the recitation of the components themselves" (MPEP 2173.05(e)). However, solely to expedite issuance of the claims, Applicants have amended Claim 18 to remove "the" from line 1, thereby overcoming the Examiner's rejection of Claims 18 and 19-32.

The Examiner has further rejected Claim 18 for allegedly being vague and indefinite. Applicants have amended Claim 18 in order to address this rejection. Support for the amendments to Claim 18 may be found, for example on page 1 paragraph 3 (lines 20-23), page 2 paragraph 4 (lines 2-6), page 9 paragraph 34 (lines 28-30) and page 16 paragraph 56 (lines 2-6) of the Specification. Applicants respectfully submit that these amendments do not present new matter and that the rejection of Claims 18 and 19-32 should be withdrawn.

Claim 20 is rejected for alleged lack of proper antecedent basis and Claims 21-32 are rejected for being dependent upon the rejected claim 20. Applicants have amended Claim 20 to recite "the step of *detecting* candidate fragments" and respectfully submit that the rejection of Claims 20 and 21-32 be withdrawn.

The Examiner has rejected Claim 28 because it recites the range "10-50" without stating to what components this range refers. Claims 29-32 are also rejected since they

Serial No.: 09/683,258
Attorney Docket: 3418

are dependent on the rejected Claim 28. Applicants have amended Claim 28 to recite "10-50 bp" and request that the rejection of Claims 28 and 29-32 be withdrawn.

The Examiner has rejected Claim 31 for alleged lack of antecedent basis and Claim 32 for being dependent on the rejected Claim 31. Applicants have amended Claim 31 to overcome the Examiner's rejection and submit that the rejection of Claim 32 also be withdrawn.

In view of the above remarks and amendments, Applicants respectfully request that the rejection of Claims 18-32 under 35 U.S.C. §112, second paragraph, be withdrawn.

Claim Rejections under 35 U.S.C. §102 should be Withdrawn

Claims 18, 19, 20 and 22 are rejected under 35 U.S.C. §102(a) for allegedly being anticipated by Pugh et al. (Genome Biology, 2001) and Ren et al. (Science, 2000).

Applicants respectfully disagree with the Office Action. Pugh et al. and Ren et al. are concerned with obtaining *individual* profiles of genomic DNA binding sites of yeast transcriptional activators such as Gal4 and Ste12. The instant invention, on the other hand, is directed to obtaining profiles of a plurality of proteins on a genome-wide scale in a high-throughput format (see page 1, lines 20-23 of the Specification).

However, solely to expedite the issuance of the Claims, Applicants have amended Claim 18 to recite "*a plurality of proteins, wherein the plurality of proteins comprise at least 50 proteins*". Support for this amendment may be found, for example on page 1 paragraph 3 (lines 20-23) and page 2 paragraph 4 (lines 2-6) of the Specification.

Serial No.: 09/683,258
Attorney Docket: 3418

In summary, since the cited references fail to disclose each and every element of the present invention, Applicants respectfully submit that the rejection of Claims 18, 19, 20 and 22 under 35 U.S.C. § 102(a) should be withdrawn.

CONCLUSION

For these reasons, Applicants believe the application is now in condition for allowance and should be passed to issue. If the Examiner feels that a telephone conference would in any way expedite the prosecution of the application, please do not hesitate to call the undersigned at (408) 731-5000.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 01-0431.

If the Examiner has any questions pertaining to this application, the Examiner is requested to contact the undersigned agent.

Respectfully submitted,



Priyadarshini Rath

Limited Recognition under 37 CFR 10.9(b)

Dated: January 22, 2004

Customer No. 22886
Legal Department
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051
Tel: 408/731-5000
Fax: 408/731-5392